ART Is Not A Luxury!
by H.S. AyoubBioHealth Investor.com One of the most over-used arguments against assisted reproductive technology (ART) is that couples do not need it. Opponents continually point out that adoption is a great way of giving…
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 377Dendreon Conference Call Transcript Summary (MAR 29, 2007)
Dendreon (DNDN-NASDAQ) spoke on a planned conference call this evening that was moved to 6:30 PM EST rather than the 7:30 PM EST planned time. They probably had a major steak dinner and 12…
Dendreon’s Big Day
This was Dendreon’s (DNDN-NASDAQ) big day, and may be what will end up as the largest battleground stock so far in 2007. This situation for Dendreon was hardly covered at all until the end…
Something More To Targeted Genetics? (TGEN)
Targeted Genetics (TGEN) is doing something unbelievable today. The company posted actual earning this morning when it was supposed to lose money according the entire large coverage universe of one single analyst. The company…
Wednesday’s Top Biotech & Medical Stocks
Biotechnology DENDREON CORP +12.99% DIVERSA CORP +11.11% CYTOKINETICS +10.57% BIOSANTE PHARMA INC +8.48% CYTORI THERAPEUTICS +7.14% Diagnostic Substances NYMOX PHARM CORP +12.41% RG GLBL LIFESTYLS +9.68% GENE LOGIC INC +7.18% HEALTHCARE TECH LTD +4.72%…
Tuesday’s Top Biotech & Medical Stocks
From BioHealth Investor by H.S. AyoubBioHealth Investor.com Biotechnology NUVELO INC NEW +24.92% NEOSE TECH INC +20.67% CARDIOVASCULAR BIOTH +18.18% CV THERAPEUTICS I +17.93% REGENERON PHARMACE +14.88% Diagnostic Substances AVANT IMMUNOTHERAP +10.53% QUIDEL CP +7.43%…
eXegenics: Dr.Frost Continues His Hot Hand
by H.S. AyoubBioHealth Investor.com Back in February, I recommended investing in Continucare (CNU) after doctor Phillip Frost, founder of Ivax Corporation, purchased shares of the healthcare company. I also explained how it seemed that…
Dendreon’s Last Day (Ahead of the FDA)
Dendreon (DNDN-NASDAQ) has only 1 trading day left before its FDA panel meeting over the potential backing of its Provenge tomorrow. The FDA issued some critical postings last night ahead of its review that…
Patient Investors: Take a Look at Amgen
From Chad Brand at Peridot Capitalist As a value investor, it is often easier to find undiscovered or unloved stocks in the small and mid cap universe. After all, bigger companies are well known,…
Weekly Top Biotech and Medical Business Articles
From BioHealth Investor by H.S. AyoubBioHealth Investor.com The following articles were the most popular at BioHealth Investor for the week of March 17 – March 23. This list can also be found on the…
CombinatoRx, Maybe Not As Bad As It Looked
CombinatoRx (CRXX) is still down in after-hours trading, but nowhere near the levels that it looked like the stock was trading at. The stock was initially down more than 20% after the news came…
Biotech Implosion: CombinatoRx (CRXX)
If having a difficult to say and spell name wasn’t bad enough, issuing poor study results will do it. CombinatoRx, Inc. (CRXX-NASDAQ) just announced preliminary results of a Phase II clinical trial studying CRx-139…
Two Less Followed Stent-Related Companies At Risk
There are two companies that are not as frequently referred to in stent-land, and depending on how you interpret today’s news that stents don’t improve lives any better than dugs alone could really bite…
Boston Scientific Bad Hair Day: Stent Applications Narrow
A new, very large test, shows that bare-metal stents barely work in patients with chronic chest pain who have their heart disease managed with medicine. Boston Scientific needs stent use to continue to rise…
Pfizer Gets Bitten
Life does not get any easier for Pfizer (PFE). Forget generics. Now other drug firms are ganging up on them. Merck (MRK) and Schering-Plough are going to offer drug that combines their cholestoral drug…